Figure 1.
Study flow of HIV-infected patients who developed hepatotoxicity after treatment with trimethoprim/sulfamethoxazole.
Table 1.
Clinical characteristics of HIV-infected patients with and those without hepatotoxicity after receiving trimethoprim/sulfamethoxazole for treatment of Pneumocystis jirovecii pneumonia.
Table 2.
Virologic, immunologic and clinical status of HIV infection and treatment of HIV-infected patients with and those without hepatotoxicity after receiving trimethoprim/sulfamethoxazole.
Table 3.
Other TMP/SMX-associated complications of HIV-infected patients with and those without hepatotoxicity after receiving trimethoprim/sulfamethoxazole.
Table 4.
Multivariate logistic regression for the factors associated with trimethoprim/sulfamethoxazole-related hepatotoxicity.
Figure 2.
Trends of incidence of trimethoprim/sulfamethoxazole-related hepatotoxicity (Y-axis) and daily dose of fluconazole in mg/kg (X-axis) (P for trends, 0.343).
Figure 3.
Metabolic pathways of sulfamethoxazole.